/ Print /

  • linkedin
  • Increase Font
  • Sharebar

    Biosimilars and interchangeable biologics: News to watch


    Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain

    During the session, “Interchangeable Biologics and Biosimilars: The Federal and State Perspective” at the Academy of Managed Care Pharmacy (AMCP) Nexus on October 5, presenters shed some light on these issues.

    Biosimilar, not a bioequivalent

    Kevin M. Nelson, JD, partner at Duane Morris LLP, in Chicago, who copresented with Sean Karbowicz, PharmD, RPh, founder and lead pharmacist at MedSavvy, in Portland, Oregon, stressed that a biosimilar is not a bioequivalent. It must be “highly similar” to the reference product, notwithstanding minor differences in clinically inactive components, he said.  

    So what does “highly similar” mean? According to the statute, it means there are no clinically meaningful differences in terms of safety, purity, and potency between the biosimilar and reference product, said Nelson.

    The FDA requires that a biosimilar must have the same mechanism of action, routes of administration (ROA), conditions of use, dosage form, and strength as the referenced product, he said.

    Nelson cited the FDA’s 2012 draft guidance that provides three ways a biosimilar can be different from the reference product (provided it shows biosimilarity):

    · Different formulation;

    · Can seek approval for less than all ROA; and

    · Can seek approval for less than all indications.

    Where we are now

    While Europe has had a biosimilar pathway since 2006, biosimilars didn’t get into the books in the U.S. until 2012, and we didn’t really get moving on biosimilars until 2015, said Nelson.

    Currently, four biosimilars are approved in the U.S. (with two approvals occurring in the last 2.5 months), he said. “The U.S. is lagging far behind, Europe has a proven track record now of getting biosimilars safely on the market and paid for.”

    Nelson said the slow progress is due to scientific, regulatory, payment, naming, coding, and litigation barriers (such as patent disputes). Of litigation, he said, “This is really what’s right now stopping some of our biosimilar products from getting on the market.”

    The first approved biosimilar was Sandoz’s Zarxio (filgrastim-sndz), approved in March 2015 and launched in September 2015. This noninterchangeable biosimilar to Amgen’s Neupogen (filgrastim), initially sold at a 15% discount off the wholesale price.

    “While it was the first biosimilar on the market, it provided us an example for getting a biosimilar approved, but not necessarily the example for getting a biosimilar approved,” said Nelson.

    Other biosimilars approved, but not yet sold are:

    · Inflectra (infliximab-dyyb)

    · Sandoz’s Erelzi (etanercept-szzs)

    · Amgen’s Amjevita (adalimumab-atto)

    Next: Interchangeable biologics



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Follow Us On Twitter

    Find us on Facebook

    Latest Tweets Follow